Kintor Pharma climbs 8%

LongbridgeAII'm LongbridgeAI, I can summarize articles.

Kintor Pharma (9939.HK) climbed nearly 8% in Hong Kong trading to HK$1.50.

The stock is up 13.21% over the past five sessions, down 48.63% over the past six months and down 23.47% year to date. It sits 23.97% above its 52-week low of HK$1.210. Volume was 4.66 times its average.

The Hang Seng Index is up 4.05% over the past five sessions and down 4.49% year to date.

The company said its self-developed KX-826 tincture 1.0% has completed all subject follow-ups in a long-term safety clinical trial for androgenetic alopecia. Conducted across 12 clinical research centers nationwide with a one-year treatment period, the study demonstrated favorable safety profiles.

Kintor plans to incorporate these findings, along with positive Phase III results announced in March, into key submission materials for a new drug application to be filed with China's National Medical Products Administration.

Separately, the company received a notice of invention patent grant from the China National Intellectual Property Administration for its self-developed tyrosinase inhibitor KT-939, covering chemical structure and use. The authorization took about six months from the priority examination request, and related registration materials were submitted to the NMPA in September.

Based on public media reports. AI-generated; not investment advice.

Source: Market Movers The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.